Introduction
Timely reperfusion therapy, especially via primary percutaneous coronary intervention (pPCI), plays a key role in the treatment of the ST-segment elevation myocardial infarction (STEMI), and it contributes to a marked decrease in the acute mortality of patients with STEMI (1). However, the ischemic/reperfusion injury following pPCI remains unsolved and results in a lower myocardial survival rate and a higher morbidity of heart failure (2, 3) . Coronary microvascular obstruction (CMVO) and myocardial injury widely existed in patients with acute myocardial infarction (AMI) after the treatment with PCI, contributing to the final infarct size (IS) (3) (4) (5) (6) . The IS is the major determinant of the adverse cardiac remodeling associated with unfavorable prognosis. Disappointingly, a vast number of clinical studies had not yet identified a solid strategy to diminish IS (4, (6) (7) (8) . Thus, it is necessary to explore novel therapeutics.
Nicorandil, a combined agent with an adenosine triphosphate-sensitive K (K ATP ) channel agonist and nitrate preparation, could improve clinical outcomes for ischemic heart disease through relieving both microcirculation dysfunction and myo-cardial injury (9) (10) (11) . Additionally, several experimental studies had observed that nicorandil could reduce myocardial IS by approximately 50% (12) (13) (14) . However, it is still controversial whether nicorandil diminishes IS in patients with acute myocardial infarct (15) . Indeed, nicorandil was mostly administered a short time before PCI or during the perioperative period in previous trials (15, 16) . However, microvascular obstruction would still deteriorate continuously after pPCI, and myocardial stunning may require several days or weeks to recover (10, 17) . Thus, we decided to assess the effects of continuous oral nicorandil administration on decreasing IS and improving the outcome for STEMI patients with pPCI.
Methods Patients
This trial was a pilot study with a prospective, randomized, open-label, and controlled design. One hundred thirty-four patients with their first STEMI were recruited consecutively in the Cardiac Care Unit of Xijing Hospital from September 2016 to February 2017. Briefly, inclusion criteria were as follows: (a) age between 18 and 79 years; (b) first STEMI diagnosis and prepared for pPCI treatment; and (c) within 12 hours from the onset of symptoms to hospital admission. The diagnosis of STEMI was given according to chest pain lasting for more than 30 minutes, at least 1 mm ST-segment elevation in two contiguous leads, and an increase in cardiospecific biomarkers.
Exclusion criteria were as follows: (a) previous myocardial infarction or cardiomyopathy; (b) culprit lesion in the left main trunk with hemodynamic instability; (c) Killip classification III or IV; (d) failure to open occlusion by pPCI or transferred to coronary artery bypass grafting; (e) glucose control with sulfonylureas (K ATP channel inhibitor); (f) severe liver, kidney, or lung diseases; (g) history of drug allergy; and (h) severe glaucoma.
After meeting the eligibility criteria, patients with STEMI were assigned to the nicorandil group or the control group according to a stochastic sequence generated via the computer. All patients were given 5 mg of oral nicorandil after the hospital admission. Then, the nocorandil group was given 5 mg nicorandil three times a day for 6 months following PCI. Other treatments were completed according to the standard guidelines for both groups.
Protocols
All patients enrolled were treated on the basis of the current guidelines and recommendations for the management of patients with STEMI. Nicorandil was administered as an adjuvant treatment.
Once emergency patients were diagnosed with STEMI, dual antiplatelet therapy was given with a loading dose of aspirin, ticlopidine, or clopidogrel. Prior to catheterization, all patients received intravenous heparin (70 IU/kg). The pPCI procedure was performed in a standardized manner. Patients with no-reflow (TIMI flow grade ≤2) were treated with tirofiban, intracoronary sodium nitroprusside or adenosine in the catheterization laboratory. Statins, beta-blockers, angiotensin-converting enzyme inhibitor (ACEI), and angiotensin receptor blocker (ARB) were given according to the patient condition.
Electrocardiography was performed before entering the catheterization laboratory. Blood samples were taken to measure the levels of cardiospecific enzymes or biomarkers, such as CK-MB and Troponin I (TnI), after admission and 24 hours after PCI. Resting ECG-gated single-photon emission computed tomography (SPECT) was performed at 3 months after PCI. As described previously (18) , the SPECT image acquisition began 50-60 min after the technetium-99 m-sestamibi injection (740-900 MBq, weight adjusted). After processing and reconstructing, an image analysis was performed using an Entegra (GE Medical Systems) processing station. The area of the deficiency was quantified with a threshold of 50% of the peak uptake. The IS was expressed as a percentage of the left ventricle. Echocardiography (Philips Ultrasound, Washington, USA) was performed to assess the left ventricular ejection fraction (LVEF) at admission, 1, 3, and 6 months after PCI. As our previous methods (18) , echocardiograms were measured by two experienced cardiac ultrasound technicians blinded to the groups. If a discrepancy between the readings of >5% was noted, a third observer participated, and a consensus was achieved. The interobserver variability analysis showed a good repeatability (LVEF, 1.2±4.1%) with the Bland-Altman test. The Seattle Angina Questionnaire (SAQ) was recorded at 6 months. SAQ was applied to measure specific health conditions and the quality of life in coronary artery disease, including physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception (18) . Additionally, we also collected major cardiac adverse events (MACE), including allcause death, myocardial reinfarction, severe heart failure, and unplanned rehospitalization from a cardiac cause. Those examinations were performed by experienced colleagues who were blinded.
The primary endpoint was the IS, quantified as a percentage of LV wall, was evaluated by SPECT at 3 months. The secondary endpoints were LVEF and SAQ assessed at 6 months. Our study was approved by the Ethical Committee of Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. The protocol has been registered at www.chictr.org.cn/ (Clinical Trials number, ChiCTR-IPC-16009477). All of the patients gave their written, informed consent.
Statistical analysis
This study was a superiority trial, and the primary purpose was to observe whether sustained oral nicorandil reduced myocardial IS. We defined the power of the statistical test (1-β) as 0.8, the significance level α as 0.05. As in the current literature, the standard deviation (SD) of IS was assessed by SPECT, rang-ing from 4% to 18% (18) (19) (20) . We supposed that the mean±SD of IS for the nicorandil group was 15%±10% and that the IS for the control group was 20%±10%. A sample size of 50 patients would be required in each group. Given the ratio of loss for follow-up or withdrawal was 10%, the population that we needed was no less than 110. Taking into consideration that some patients refused or were unsuited for SPECT, we recruited another 10 patients consecutively.
Statistical analysis was based on the principle of Intention to Treat. Continuous data with a normal distribution were expressed as the means and standardized deviations, compared by Student's t-test. If normality tests failed, the data were described as medians and interquartile ranges (IQR) and assessed by the Mann-Whitney U test. Categorical parameters were presented as a proportion or number, compared with the chi-square test or Fisher's exact test. To perform a subgroup analysis, we transformed the primary endpoint of IS, to binary data [defining greater than or equal the median of IS (14%) as larger area]. The risk ratio and 95% confidence intervals were estimated and analyzed by a logistic regression analysis. Statistical analysis was performed with the SPSS software package (SPSS, version 14.0, Chicago, IL, USA) and STATA (StataCorp LP, version 10, College Station, Texas, USA). All tests were two-sided, and p-value of <0.05 was considered to be statistically significant. several reasons (Killip III-IV class, previous MI, renal failure, and oral sulfonylureas), and 117 patients were eligible in our study. The baseline characteristics of the patients are presented in Table 1 . Finally, 99 patients with a first STEMI diagnosis in both groups completed the follow-up at 6 months. No significant difference was observed with regard to LVEF, CK-MB, and TnI before pPCI and coronary angiography features, indicating that the cardiac injury level in both groups may be similar before reperfusion ( Table 1) . The impact of nicorandil on IS was evaluated by SPECT 3 months after pPCI and expressed as a percentage of the left ventricle wall ( Fig. 2 and Table 2 ). Actually, only 85 patients performed the SPECT scan and were suitable for an IS assessment. No statistically significant difference of population characteristics was observed in the subjects who received the SPECT examination Table 1 Table 2 and Supplemental Fig. 1 ]. Maintained nicorandil also improved the quality of life for STEMI patients (Table 2 and Supplemental Fig. 2) . The follow-up data of SAQ 6 months post-pPCI indicated that continual nicorandil treatment ameliorated physical limitations (73.3±14.07 vs. 67.4±13.21, p=0.034) and angina stability (63.8±10.74 vs. 55.8±12.10 p=0.001). A subgroup analysis did not reveal any statistical heterogeneity with regard to age, body mass index, diabetes mellitus, current smoking status, symptom onset-balloon time, and left anterior descending coronary artery (Fig. 3) . No significant difference in the incidence of adverse cardiac events was observed (Supplemental Table 2 ).
Results

Discussion
This study shows that compared with a single oral nicorandil treatment, sustained administration of nicorandil reduced myoSupplemental MACE includes all-cause death, myocardial reinfarction, severe heart failure, and unplanned rehospitalization from a cardiac cause. There was no significant difference in the incidence of adverse cardiac events. MACE -the major adverse cardiac events
Supplemental Figure 1 . Effects of long-term nicorandil administration on cardiac function Left ventricular ejection fraction (LVEF) assessed by echocardiography at admission to hospital, and 1, 3, and 6 months after PCI. Sustained oral nicorandil treatment led to a significant improvement in LVEF at 3 months. Additionally, there was still a tendency toward a higher LVEF at 6 months, although the difference between both groups was moderate. The columns and error bars represent the median and interquartile ranges (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (21) . The main purpose of our trial is to investigate the cardioprotective effects of continual nicorandil treatment on IS reduction in patients with STEMI and Killip I-II.
As it has a unique structure, nicorandil has a variety of cardiac protective mechanisms through the K ATP channel agonism and NO pathways. Nicorandil effectively improves the symptoms and outcomes of ischemic heart disease (11, 22) . In addition to relaxing large coronary vessels via NO, nicorandil dilates the microvasculature to improve cardiac perfusion by activating K ATP channels specifically. Nicorandil also protects myocytes through opening K ATP channels located in the sarcolemma and mitochondrion under ischemia-reperfusion conditions (9) . Moreover, nicorandil has other cardioprotective mechanisms, such as inhibiting apoptosis and regulating cardiac sympathetic nerve activity and mediating autophagy (23) (24) (25) .
According to the mechanisms described above, nicorandil may have a promising effect that can lessen the IS for AMI patients.
As expected, animal experiments demonstrated that nicorandil reduced the infarct area by 52%-54.9% via activating the K ATP channel (12, 13) . Nevertheless, whether nicorandil limited the IS of patients with STEMI was still controversial. The J-WIND study aimed to assess whether nicorandil reduced the IS in patients with STE-MI. Unexpectedly, nicorandil could not decrease the IS assessed by creatine kinase compared to the placebo. Another small study performed by Yamada et al. (16) enrolled 55 patients with AMI undergoing pPCI and administered intracoronary nicorandil or nitrate for 4 days. Their data revealed that nicorandil reduced IS by 18.9% compared with nitrate. In our study, the results exhibited that sustained oral nicorandil administration had the effect of reducing IS for patients STEMI undergoing pPCI.
Presumably, several reasons may explain this inconsistency. The J-WIND study employed continuous monitoring of CK to estimate IS indirectly. Although some studies indicated CK and CK-MB were associated with IS (correlation coefficient, 0.55-0.73). These biomarkers could only be thought as predictors of IS but not instead IS itself (21, 26, 27) . Because reperfusion attached a rapid washout of CK in the ischemic band, it may affect the IS estimate (27) . Second, the dosage impacted its effect. Previous studies also suggested that nicorandil improved exercise tolerance, cardiac function, and myocardial injury for CAD patients in a dose-dependent fashion. J-WIND study investigators also inferred the dosage of nicorandil is insufficient. Similarly, the primary endpoint in our trial was below expectations and may also be associated with dosage. Additionally, the time of medication may also be significant for nicorandil. In the J-WIND study, patients received intravenous nicorandil for 1 day, and no difference was observed. In Yamada et al. (16) study, nicorandil was given continuously for 4 days with a positive result. We evaluated IS at 3 months with continual oral nicorandil, and the above results may also support this point. In fact, there still remained persistent microvascular obstruction even at 6-10 days after MI (28, 29) . Meanwhile, the stunned myocardium may need several weeks to recover contractile function (17, 30) . Therefore, our trial, and previous studies, indicated that continuously alleviating CMVO and protecting cardiomyocytes were beneficial for saving variable myocadium.
In the present study, it was observed that the TnI level, rather than CK-MB, was statistically lower in the continual nicorandil group compared to the control group. The biomarker level was not measured successively, and those data only suggest that TnI at 24 h after PCI may be more sensitive than CK-MB to predict IS. Furthermore, other researchers observed early the CK-MB level at 4-12 h after PCI was a good predictor for IS, which may also support this point (26, 31) . Consistent with previous reports, our results also indicated that sustained nicorandil administration elevated LVEF and the quality of life (15, 32) . However, we did not observe a significant difference in LVEF at 6 months for both groups. Partly because the recovery of cardiac function existed in both groups as time passed, more patients were required to survey the effect. Additionally, numerous studies have demonstrated that nicorandil decreased the occurrence of MACE (11, 33) . In this study, continuous nicorandil did not clearly affect the incidence of MACE, partly due to an insufficient sample size.
Study limitations
Several limitations existed in this study. First, the SPECT was chosen to assess IS in our study. Indeed, delayed enhancement CMR has a better spatial resolution to detect small myocardial infarcts than single-photon emission computed tomography (34) . Second, we assessed IS at 3 months according to the equivalent myocardial injury of baseline. We did not collect the data about the area at risk at cute phases. Thus, the myocardial salvage index was not observed. Third, a follow-up for 6 months and a small sample size were insufficient to assess the long-term clinical outcomes and further subgroup analysis. Fourth, we just administered a routine dosage in this pilot study. The difference on IS was modest with 30% primary endpoint missing that resulted in possible selection bias. So it was not enough to be a clinical directive. Nicorandil plays a variety of biological roles in a dose-dependent manner (35) (36) (37) , suggesting it may also reduce IS this way. Thus, the extent to which IS can be reduced by adjusting nicorandil administration still needs to be studied. Considering the distinct pathophysiology in the acute phase, we could further investigate the cardiac protective effect of nicorandil with sequential therapy, giving a large dose in the first week and continual standard doses thereafter.
Conclusion
A single administration of nicorandil before PCI may be insufficient to exert its protective effects. Our results suggest that sustained nicorandil administration has a more beneficial effects on reducing IS and improving clinical outcomes for patients with STEMI undergoing pPCI. Furthermore, continual pharmaceutical administration seems to be a promising strategy to reduce the necrosis area compared with short-term intervention after the onset that needs further validation.
